<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="15989">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00090220</url>
  </required_header>
  <id_info>
    <org_study_id>V501-019</org_study_id>
    <secondary_id>2004_013</secondary_id>
    <nct_id>NCT00090220</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501) in Women (V501-019)</brief_title>
  <official_title>Safety, Immunogenicity, and Efficacy of Gardasil (V501 (Human Papilloma Virus [Types 6, 11, 16, 18] Recombinant Vaccine) in Mid-Adult Women - The FUTURE III (Females United to Unilaterally Reduce Endo/Ectocervical Cancer) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to assess the tolerability and efficacy of a vaccine being evaluated to reduce
      the incidence of human papillomavirus (HPV) infection and disease (external genital warts
      and vulvar, vaginal, and cervical cancer) in women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The base study (V501-019) encompassed Day 1 through Month 7, during which time participants
      received randomly assigned Gardasil™ (qHPV vaccine) or placebo at Day 1, Month 2 and Month
      6. Base study follow-up continued through Month 48.

      The base study was extended in protocol V501-019-10 (EXT1). Participants who received
      placebo and participants who received only 1 dose of qHPV vaccine in the base study were
      offered a complete 3-dose qHPV vaccine regimen (administered at EXT1 Day 1, Month 2 and
      Month 6). Participants who received only 2 doses of qHPV vaccine in the base study were
      offered a single additional dose of qHPV vaccine (administered at EXT1 Day 1). Participants
      were followed to EXT1 Month 7.

      A Long Term Follow-Up (LTFU) extension study V501-019-20 (EXT2) will observe the long term
      safety, effectiveness, and immunogenicity of GARDASIL™ in 1,600 women who participated in
      the base protocol in Colombia. Data will be collected over a period of 6-10 years following
      subjects' enrollment in the original base protocol.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Combined Incidence of HPV 6/11/16/18 Related Persistent Infection, Genital Warts, Vulvar Intraepithelial Neoplasia (VIN), Vaginal Intraepithelial Neoplasia (VaIN), Vulvar Cancer, Vaginal Cancer, Cervical Dysplasia, AIS, and Cervical Cancer</measure>
    <time_frame>Base Study: through Month 48</time_frame>
    <safety_issue>No</safety_issue>
    <description>HPV 6/11/16/18: The four types of HPV (types 6/11/16/18) were determined by polymerase chain reaction (PCR) testing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Vaccine-Related Serious Adverse Events (SAEs)</measure>
    <time_frame>Base Study: through Month 48</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Combined Incidence of HPV 6/11 Related Persistent Infection, Genital Warts, VIN, VaIN, Vulvar Cancer, Vaginal Cancer, Cervical Dysplasia, Adenocarcinoma In Situ (AIS), and Cervical Cancer</measure>
    <time_frame>Base Study: through Month 48</time_frame>
    <safety_issue>No</safety_issue>
    <description>HPV 6/11: The two types of HPV (types 6/11) were determined by PCR testing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined Incidence of HPV 31/33/35/52/58 Related Persistent Infection, Genital Warts, VIN, VaIN, Vulvar Cancer, Vaginal Cancer, Cervical Dysplasia, Cervical AIS, and Cervical Cancer</measure>
    <time_frame>Base Study: through Month 48</time_frame>
    <safety_issue>No</safety_issue>
    <description>This outcome measure was not analyzed because of diminished interest by experts in composite efficacy endpoints associated with these HPV types</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Combined Incidence of HPV 16/18 Related Persistent Infection, Genital Warts, VIN, VaIN, Vulvar Cancer, Vaginal Cancer, Cervical Dysplasia, Cervical AIS, and Cervical Cancer</measure>
    <time_frame>Base Study: through Month 48</time_frame>
    <safety_issue>No</safety_issue>
    <description>HPV 16/18: The two types of HPV (types 16/18) were determined by PCR testing</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3819</enrollment>
  <condition>Healthy</condition>
  <condition>Papillomavirus Infection</condition>
  <arm_group>
    <arm_group_label>qHPV Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gardasil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine</intervention_name>
    <description>Gardasil intramuscular injection in three 0.5 mL doses over 6 months.</description>
    <arm_group_label>qHPV Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: Placebo</intervention_name>
    <description>Placebo intramuscular injection in three 0.5 mL doses over 6 months.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  No history of genital warts, VIN, or VaIN

          -  Not pregnant and agrees to use effective contraception through Month 7 of the study

          -  Additional criteria will be discussed with you by the physician

        Exclusion Criteria:

          -  Pregnant

          -  Concurrently enrolled in a clinical study involving collection of cervical specimens

          -  Previously received any HPV vaccine

          -  History of severe allergic reaction that required medical intervention

          -  Received any immune globulin or blood-derived products within 3 months prior to the
             first study injection

          -  History of splenectomy, known immune disorders, or receiving immunosuppressives

          -  Immunocompromised or diagnosed with HIV infection

          -  Known thrombocytopenia or any coagulation disorders that could contraindicate
             intramuscular injections

          -  History of recent or ongoing alcohol or drug abuse

          -  Prior treatment for genital warts, VIN, or VaIN

          -  History of cervical disease (ie, surgical treatment for cervical lesions)

          -  Hysterectomy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>24 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <reference>
    <citation>Muñoz N, Manalastas R Jr, Pitisuttithum P, Tresukosol D, Monsonego J, Ault K, Clavel C, Luna J, Myers E, Hood S, Bautista O, Bryan J, Taddeo FJ, Esser MT, Vuocolo S, Haupt RM, Barr E, Saah A. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet. 2009 Jun 6;373(9679):1949-57. doi: 10.1016/S0140-6736(09)60691-7. Epub 2009 Jun 1.</citation>
    <PMID>19493565</PMID>
  </reference>
  <reference>
    <citation>Velicer C, Zhu X, Vuocolo S, Liaw KL, Saah A. Prevalence and incidence of HPV genital infection in women. Sex Transm Dis. 2009 Nov;36(11):696-703. doi: 10.1097/OLQ.0b013e3181ad25ff.</citation>
    <PMID>19652630</PMID>
  </reference>
  <results_reference>
    <citation>Castellsagué X, Muñoz N, Pitisuttithum P, Ferris D, Monsonego J, Ault K, Luna J, Myers E, Mallary S, Bautista OM, Bryan J, Vuocolo S, Haupt RM, Saah A. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. Br J Cancer. 2011 Jun 28;105(1):28-37. doi: 10.1038/bjc.2011.185. Epub 2011 May 31.</citation>
    <PMID>21629249</PMID>
  </results_reference>
  <verification_date>January 2016</verification_date>
  <lastchanged_date>January 20, 2016</lastchanged_date>
  <firstreceived_date>August 25, 2004</firstreceived_date>
  <firstreceived_results_date>October 30, 2009</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Papillomavirus Infections</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>qHPV Vaccine in Base Study</title>
          <description>The vaccination period for the base study encompassed Day 1 through Month 7, during which time participants received qHPV vaccination at Day 1, Month 2 and Month 6.
Follow-up for the base study encompassed Month 7 through Month 48.</description>
        </group>
        <group group_id="P2">
          <title>Placebo in Base Study</title>
          <description>The vaccination period for the base study encompassed Day 1 through Month 7, during which time participants received placebo at Day 1, Month 2 and Month 6.
Follow-up for the base study encompassed Month 7 through Month 48.</description>
        </group>
        <group group_id="P3">
          <title>EXT1: Placebo in Base Study</title>
          <description>Participants in the placebo arm in the base study were offered 3 doses of open-label qHPV vaccine at EXT1 Day 1, Month 2 and Month 6. Participants were followed to EXT1 Month 7</description>
        </group>
        <group group_id="P4">
          <title>EXT1: Incomplete qHPV Regimen in Base Study</title>
          <description>Participants who received placebo and participants who received only 1 dose of qHPV vaccine in the base study were offered a complete 3-dose qHPV vaccine regimen (administered at EXT1 Day 1, Month 2 and Month 6). Participants who received only 2 doses of qHPV vaccine in the base study were offered a single additional dose of qHPV vaccine (administered at EXT1 Day 1). Participants were followed to EXT1 Month 7.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Base Study Vaccination Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1911"/>
                <participants group_id="P2" count="1908"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated</title>
              <participants_list>
                <participants group_id="P1" count="1910"/>
                <participants group_id="P2" count="1907"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1847"/>
                <participants group_id="P2" count="1845"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="63"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Randomized not Vaccinated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient Moved</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Deviation from Protocol</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unspecified</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Base Study Follow-up Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1855">8 participants did not complete the Vaccination Period but did enter the Follow-up Period.</participants>
                <participants group_id="P2" count="1851">5 participants did not complete the Vaccination Period but did enter the Follow-up Period.</participants>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1684">11 participants continued in base study follow-up as of 30 April 2009</participants>
                <participants group_id="P2" count="1677">10 participants continued in base study follow-up as of 30 April 2009</participants>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="171"/>
                <participants group_id="P2" count="174"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="88"/>
                <participants group_id="P2" count="78"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="36"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient Moved</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No Final Visit before study cutoff date</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unspecified</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study Still Ongoing</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Extension 1 (EXT1)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1322">Participation in EXT1 was voluntary; not all participants eligible for EXT1 enrolled.</participants>
                <participants group_id="P4" count="7">Participation in EXT1 was voluntary; not all participants eligible for EXT1 enrolled.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1321"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1267"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="55"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="22"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Moved</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reason</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>qHPV Vaccine in Base Study</title>
          <description>Participants who started the base study vaccination period</description>
        </group>
        <group group_id="B2">
          <title>Placebo in Base Study</title>
          <description>Participants who started the base study vaccination period</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="1911"/>
                <measurement group_id="B2" value="1908"/>
                <measurement group_id="B3" value="3819"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="34.3" spread="6.3"/>
                <measurement group_id="B2" value="34.3" spread="6.3"/>
                <measurement group_id="B3" value="34.3" spread="6.3"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>Although the upper age limit for this study was 45 years old, one subject 46 years of age was randomized into the study.</description>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="35" lower_limit="24" upper_limit="45"/>
                <measurement group_id="B2" value="34" lower_limit="21" upper_limit="46"/>
                <measurement group_id="B3" value="34" lower_limit="21" upper_limit="46"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1911"/>
                <measurement group_id="B2" value="1908"/>
                <measurement group_id="B3" value="3819"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="596"/>
                <measurement group_id="B2" value="596"/>
                <measurement group_id="B3" value="1192"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="100"/>
                <measurement group_id="B2" value="82"/>
                <measurement group_id="B3" value="182"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Hispanic American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="822"/>
                <measurement group_id="B2" value="827"/>
                <measurement group_id="B3" value="1649"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Native American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="3"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="388"/>
                <measurement group_id="B2" value="397"/>
                <measurement group_id="B3" value="785"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Multi-Racial</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
                <measurement group_id="B2" value="4"/>
                <measurement group_id="B3" value="7"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Polynesian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Combined Incidence of HPV 6/11/16/18 Related Persistent Infection, Genital Warts, Vulvar Intraepithelial Neoplasia (VIN), Vaginal Intraepithelial Neoplasia (VaIN), Vulvar Cancer, Vaginal Cancer, Cervical Dysplasia, AIS, and Cervical Cancer</title>
        <description>HPV 6/11/16/18: The four types of HPV (types 6/11/16/18) were determined by polymerase chain reaction (PCR) testing</description>
        <time_frame>Base Study: through Month 48</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per-protocol population: subjects must have no major protocol violations, must be seronegative to the relevant HPV type at Day 1 and polymerase chain reaction (PCR) negative to the relevant HPV type Day 1 through Month 7, and must provide follow-up data after Month 7</population>
        <group_list>
          <group group_id="O1">
            <title>qHPV Vaccine in Base Study</title>
            <description>The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time participants received qHPV vaccination at Day 1, Month 2 and Month 6.
Follow-up for the base study encompassed Month 7 through Month 48.</description>
          </group>
          <group group_id="O2">
            <title>Placebo in Base Study</title>
            <description>The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time participants received qHPV vaccination at Day 1, Month 2 and Month 6.
Follow-up for the base study encompassed Month 7 through Month 48.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1601"/>
                  <measurement group_id="O2" value="1599"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Combined Incidence of HPV 6/11/16/18 Related Persistent Infection, Genital Warts, Vulvar Intraepithelial Neoplasia (VIN), Vaginal Intraepithelial Neoplasia (VaIN), Vulvar Cancer, Vaginal Cancer, Cervical Dysplasia, AIS, and Cervical Cancer</title>
            <description>HPV 6/11/16/18: The four types of HPV (types 6/11/16/18) were determined by polymerase chain reaction (PCR) testing</description>
            <units>Incidence per 100 person-years</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.2"/>
                  <measurement group_id="O2" value="1.7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <param_type>Percent Relative Risk Reduction</param_type>
            <param_value>88.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>78.1</ci_lower_limit>
            <ci_upper_limit>94.8</ci_upper_limit>
            <estimate_desc>Confidence Interval based on binomial tail probabilities and not from a dispersion parameter.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Combined Incidence of HPV 16/18 Related Persistent Infection, Genital Warts, VIN, VaIN, Vulvar Cancer, Vaginal Cancer, Cervical Dysplasia, Cervical AIS, and Cervical Cancer</title>
        <description>HPV 16/18: The two types of HPV (types 16/18) were determined by PCR testing</description>
        <time_frame>Base Study: through Month 48</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per-protocol population: subjects must have no major protocol violations, must be seronegative to the relevant HPV type at Day 1 and PCR negative to the relevant HPV type Day 1 through Month 7, and must provide follow-up data after Month 7</population>
        <group_list>
          <group group_id="O1">
            <title>qHPV Vaccine in Base Study</title>
            <description>The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time participants received qHPV vaccination at Day 1, Month 2 and Month 6.
Follow-up for the base study encompassed Month 7 through Month 48.</description>
          </group>
          <group group_id="O2">
            <title>Placebo in Base Study</title>
            <description>The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time participants received qHPV vaccination at Day 1, Month 2 and Month 6.
Follow-up for the base study encompassed Month 7 through Month 48.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1587"/>
                  <measurement group_id="O2" value="1571"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Combined Incidence of HPV 16/18 Related Persistent Infection, Genital Warts, VIN, VaIN, Vulvar Cancer, Vaginal Cancer, Cervical Dysplasia, Cervical AIS, and Cervical Cancer</title>
            <description>HPV 16/18: The two types of HPV (types 16/18) were determined by PCR testing</description>
            <units>Incidence per 100 person-years</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.2"/>
                  <measurement group_id="O2" value="1.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <param_type>Percent Relative Risk Reduction</param_type>
            <param_value>84.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>67.5</ci_lower_limit>
            <ci_upper_limit>93.7</ci_upper_limit>
            <estimate_desc>Confidence Interval based on binomial tail probabilities and not from a dispersion parameter.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Combined Incidence of HPV 6/11 Related Persistent Infection, Genital Warts, VIN, VaIN, Vulvar Cancer, Vaginal Cancer, Cervical Dysplasia, Adenocarcinoma In Situ (AIS), and Cervical Cancer</title>
        <description>HPV 6/11: The two types of HPV (types 6/11) were determined by PCR testing</description>
        <time_frame>Base Study: through Month 48</time_frame>
        <safety_issue>No</safety_issue>
        <population>Per-protocol population: subjects must have no major protocol violations, must be seronegative to the relevant HPV type at Day 1 and PCR negative to the relevant HPV type Day 1 through Month 7, and must provide follow-up data after Month 7</population>
        <group_list>
          <group group_id="O1">
            <title>qHPV Vaccine in Base Study</title>
            <description>The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time participants received qHPV vaccination at Day 1, Month 2 and Month 6.
Follow-up for the base study encompassed Month 7 through Month 48.</description>
          </group>
          <group group_id="O2">
            <title>Placebo in Base Study</title>
            <description>The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time participants received qHPV vaccination at Day 1, Month 2 and Month 6.
Follow-up for the base study encompassed Month 7 through Month 48.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1316"/>
                  <measurement group_id="O2" value="1316"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Combined Incidence of HPV 6/11 Related Persistent Infection, Genital Warts, VIN, VaIN, Vulvar Cancer, Vaginal Cancer, Cervical Dysplasia, Adenocarcinoma In Situ (AIS), and Cervical Cancer</title>
            <description>HPV 6/11: The two types of HPV (types 6/11) were determined by PCR testing</description>
            <units>Incidence per 100 person-years</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.0"/>
                  <measurement group_id="O2" value="0.9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <param_type>Percent Relative Risk Reduction</param_type>
            <param_value>94.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>79.9</ci_lower_limit>
            <ci_upper_limit>99.4</ci_upper_limit>
            <estimate_desc>Confidence Interval based on binomial tail probabilities and not from a dispersion parameter.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Combined Incidence of HPV 31/33/35/52/58 Related Persistent Infection, Genital Warts, VIN, VaIN, Vulvar Cancer, Vaginal Cancer, Cervical Dysplasia, Cervical AIS, and Cervical Cancer</title>
        <description>This outcome measure was not analyzed because of diminished interest by experts in composite efficacy endpoints associated with these HPV types</description>
        <time_frame>Base Study: through Month 48</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>qHPV Vaccine in Base Study</title>
            <description>The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time participants received qHPV vaccination at Day 1, Month 2 and Month 6.
Follow-up for the base study encompassed Month 7 through Month 48.</description>
          </group>
          <group group_id="O2">
            <title>Placebo in Base Study</title>
            <description>The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time participants received qHPV vaccination at Day 1, Month 2 and Month 6.
Follow-up for the base study encompassed Month 7 through Month 48.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Combined Incidence of HPV 31/33/35/52/58 Related Persistent Infection, Genital Warts, VIN, VaIN, Vulvar Cancer, Vaginal Cancer, Cervical Dysplasia, Cervical AIS, and Cervical Cancer</title>
            <description>This outcome measure was not analyzed because of diminished interest by experts in composite efficacy endpoints associated with these HPV types</description>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1"/>
                  <measurement group_id="O2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Vaccine-Related Serious Adverse Events (SAEs)</title>
        <time_frame>Base Study: through Month 48</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>The population at risk was participants who received ≥1 qHPV vaccination or placebo injection in the base study</population>
        <group_list>
          <group group_id="O1">
            <title>qHPV Vaccine in Base Study</title>
            <description>The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time participants received qHPV vaccination at Day 1, Month 2 and Month 6.
Follow-up for the base study encompassed Month 7 through Month 48.</description>
          </group>
          <group group_id="O2">
            <title>Placebo in Base Study</title>
            <description>The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time participants received placebo injection at Day 1, Month 2 and Month 6.
Follow-up for the base study encompassed Month 7 through Month 48.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1908"/>
                  <measurement group_id="O2" value="1902"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Vaccine-Related Serious Adverse Events (SAEs)</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Base study: all AEs were collected systematically from Day 1 through Month 48. Extension 1: SAEs were collected systematically from Day 1 through Month 7. Other AEs were not solicited during EXT1.</time_frame>
      <desc>Medical Dictionary for Regulatory Activities (MedDRA) version 12.0 was used during the base study and follow-up; MedDRA version 14.1 was used during EXT1.
Although non-serious AEs were not solicited in EXT1, 5 participants voluntarily reported non-serious AEs (incidence &lt;1%).</desc>
      <group_list>
        <group group_id="E1">
          <title>qHPV Vaccine: Base Study</title>
          <description>The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time participants received qHPV vaccination at Day 1, Month 2 and Month 6.
Follow-up for the base study encompassed Month 7 through Month 48. The population at risk was participants who received ≥1 vaccination in the base study.</description>
        </group>
        <group group_id="E2">
          <title>Placebo: Base Study</title>
          <description>The Vaccination Period for the base study encompassed Day 1 through Month 7, during which time participants received placebo at Day 1, Month 2 and Month 6.
Follow-up for the base study encompassed Month 7 through Month 48. The population at risk was participants who received ≥1 vaccination in the base study.
Seven (7) subjects were cross treated. Cross treated subjects incorrectly received vaccination with Quadrivalent HPV vaccine and Placebo.</description>
        </group>
        <group group_id="E3">
          <title>qHPV Vaccine: EXT1</title>
          <description>Participants who received placebo and participants who received only 1 dose of qHPV vaccine in the base study were offered a complete 3-dose qHPV vaccine regimen (administered at EXT1 Day 1, Month 2 and Month 6). Participants who received only 2 doses of qHPV vaccine in the base study were offered a single additional dose of qHPV vaccine (administered at EXT1 Day 1). Participants were followed to EXT1 Month 7. The population at risk was participants who received ≥1 vaccination in EXT1 and had follow-up data.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="1328"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Hypertensive heart disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Left ventricular hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Coronary insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Hepatitis A</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Pelvic inflammatory disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Peritoneal tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Tuberculosis gastrointestinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Brain herniation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1328"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Systemic lupus erythematosus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute lymphocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Gestational trophoblastic tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Nasopharyngeal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Antepartum haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Blighted ovum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Ectopic pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>False labour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Foetal distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Premature labour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Ruptured ectopic pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Adenomyosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Dysfunctional uterine bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Fallopian tube cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Uterine haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1328"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1604" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="1482" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Hypothermia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="273" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="200" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="1423" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="1170" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Injection site pruritis</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="353" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="214" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Injection site warmth</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="219" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="232" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="98" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="101" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="88" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="88" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="526" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="519" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1908"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="1902"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication or presentation</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vice President, Late Stage Development Group Leader</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
